Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
60.57 USD | +6.08% | +4.68% | +52.34% |
03-19 | Morphic Holding Names Simon Cooper as Chief Medical Officer | MT |
03-15 | Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug | MT |
Business Summary
Number of employees: 136
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics for Hematological, Pulmonary and Cardiovascular Disorders
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 30/11/15 |
Keith Regnante
DFI | Director of Finance/CFO | 54 | 31/01/20 |
Jennifer Lachey
CTO | Chief Tech/Sci/R&D Officer | 51 | 30/06/16 |
Chief Operating Officer | 50 | 31/01/22 | |
Justin Frantz
IRC | Investor Relations Contact | - | - |
Robin Wagner
HRO | Human Resources Officer | - | 31/05/21 |
Esther Cho
LAW | General Counsel | - | 31/03/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 16/12/20 |
Carl Gordon
CHM | Chairman | 59 | 29/02/20 |
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 30/11/15 |
Tomer Kariv
BRD | Director/Board Member | 62 | 31/12/19 |
Ran Nussbaum
BRD | Director/Board Member | 51 | 31/03/16 |
Nima Farzan
BRD | Director/Board Member | 48 | 29/02/20 |
Julius Knowles
BRD | Director/Board Member | 61 | 31/03/16 |
Alpna Seth
BRD | Director/Board Member | 60 | 30/04/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,067,786 | 33,773,264 ( 93.64 %) | 0 | 93.64 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.34% | 2.18B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- KROS Stock
- Company Keros Therapeutics, Inc.